Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5419]

Single-agent PD-1 blockade as curative-intent treatment in mismatch repair...

Dr Andrea Cercek - Memorial Sloan Kettering Cancer Centre, Manhattan, New York

Single-agent PD-1 blockade as curative-intent treatment in mismatch repair-deficient locally advanced rectal cancer ( Dr Andrea Cercek - Memorial Sloan Kettering Cancer Centre, Manhattan, New York )

Review: Best options in localised prostate cancer

Prof Eleni Efstathiou, Prof Oliver Sartor, Prof Kurt Miller and Prof Karim...

Review: Best options in localised prostate cancer ( Prof Eleni Efstathiou, Prof Oliver Sartor, Prof Kurt Miller and Prof Karim Fizazi )

N-803-BCG combination shows promising results in BCG-unresponsive NMIBC

Dr Karim Chamie - UCLA School of Medicine, Los Angeles, USA

N-803-BCG combination shows promising results in BCG-unresponsive NMIBC ( Dr Karim Chamie - UCLA School of Medicine, Los Angeles, USA )

Ibrutinib improves PFS by 50% for older patients with newly diagnosed mantle...

Dr Michael Wang - MD Anderson Cancer Center, Houston, USA

Ibrutinib improves PFS by 50% for older patients with newly diagnosed mantle cell lymphoma ( Dr Michael Wang - MD Anderson Cancer Center, Houston, USA )

Everolimus after surgery can improve outcomes in those with high-risk kidney...

Dr Christopher Ryan - OHSU Knight Cancer Institute, Portland, USA

Everolimus after surgery can improve outcomes in those with high-risk kidney cancer ( Dr Christopher Ryan - OHSU Knight Cancer Institute, Portland, USA )

Circulating tumour DNA analysis can help identify the need for adjuvant therapy...

Dr Jeanne Tie - The Peter MacCallum Cancer Centre, Melbourne, Australia

Circulating tumour DNA analysis can help identify the need for adjuvant therapy in stage II colon cancer ( Dr Jeanne Tie - The Peter MacCallum Cancer Centre, Melbourne, Australia )

Sacituzumab goviteca provides clinically meaningful PFS benefit for hormone...

Dr Hope Rugo - University of California San Francisco, San Francisco, USA

Sacituzumab goviteca provides clinically meaningful PFS benefit for hormone receptor HR+/HER2‐ advanced breast cancer patients ( Dr Hope Rugo - University of California San Francisco, San Francisco, USA )

Comment: Sacituzumab govitecan for HR+/HER2‐ advanced breast cancer

Dr Jane Lowe Meisel - Winship Cancer Institute of Emory University, Georgia, USA

Comment: Sacituzumab govitecan for HR+/HER2‐ advanced breast cancer ( Dr Jane Lowe Meisel - Winship Cancer Institute of Emory University, Georgia, USA )

Circulating tumour DNA analysis can help identify the need for adjuvant therapy...

Dr Jeanne Tie - Peter MacCallum Cancer Centre, Melbourne, Australia

Circulating tumour DNA analysis can help identify the need for adjuvant therapy in stage II colon cancer ( Dr Jeanne Tie - Peter MacCallum Cancer Centre, Melbourne, Australia )

UICC announces global coalition to increase access to essential cancer...

Dr Cary Adams - Chief Executive Officer, UICC

UICC announces global coalition to increase access to essential cancer medicines in low and lower middle-income countries ( Dr Cary Adams - Chief Executive Officer, UICC )

Sacituzumab govitecan increases PFS for HR+/HER2- metastatic breast cancer

Dr Hope Rugo - University of California San Francisco, San Francisco, USA

Sacituzumab govitecan increases PFS for HR+/HER2- metastatic breast cancer ( Dr Hope Rugo - University of California San Francisco, San Francisco, USA )

Ibrutinib plus chemoimmunotherapy improved PFS for newly diagnosed MCL

Ibrutinib plus chemoimmunotherapy improved PFS for newly diagnosed MCL ( )

More from ecancer